Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;23(3):529-537.
doi: 10.1111/jch.14155. Epub 2021 Jan 7.

Assessment of preferred methods to measure insulin resistance in Asian patients with hypertension

Affiliations
Review

Assessment of preferred methods to measure insulin resistance in Asian patients with hypertension

Huynh Van Minh et al. J Clin Hypertens (Greenwich). 2021 Mar.

Abstract

Insulin resistance (IR), a metabolic risk factor, is linked to the pathogenetic mechanism of primary hypertension. Detecting IR in the patients with hypertension will help to predict and stratify the added cardiovascular risk, institute appropriate IR management, and manage hypertension optimally. There are many methods for assessing IR, each with distinct advantages and disadvantages. The euglycemic insulin clamp and intravenous glucose tolerance test, gold standards for measuring IR, are used in research but not in clinical practice. Homeostatic model assessment (HOMA-IR), a method for assessing β-cell function and IR, is frequently applied presently, particularly in Asia. Besides, the triglyceride-glucose index (TyG) first published by South American authors showed a good correlation with the insulin clamp technique and HOMA-IR index. This simple, convenient, and low-cost TyG index is of research interest in many countries in Asia and can be used to screen for IR in the Asian hypertensive community.

Keywords: Asia patients; hypertension; insulin resistance.

PubMed Disclaimer

Conflict of interest statement

CH Chen reports personal fees from Novartis, Sanofi, Daiichi Sankyo, SERVIER, and Boehringer Ingelheim Pharmaceuticals, Inc S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Hilton Pharma, Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma and ICI. All other authors report no potential conflicts of interest in relation to this article.

Similar articles

Cited by

References

    1. Olatunbosun ST, Talavera F, Griffing GT, Schade DS. Insulin resistance. Medscape. 2020. https://emedicine.medscape.com/article/122501‐overview
    1. Krentz AJ. Insulin resistance. BMJ. 1996;313:1385‐1389. - PMC - PubMed
    1. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15‐E26. - PubMed
    1. Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab. 2015;19(1):160. - PMC - PubMed
    1. Patarrãoa RS, Lauttb WW, Macedoc MP. Assessment of methods and indexes of insulin sensitivity. Rev Port Endocrinol Diabetes Metab. 2014;9(1):65‐73.